ZA200804329B - Polymorphs of androgen receptor modulator - (N-3H-imidazo [4,5-B] pyridin-2-YL-methyl)-2-fluoro-4-methyl-3-oxo-4-aza-androst- 1-EN-17. Beta, -carboxamide - Google Patents

Polymorphs of androgen receptor modulator - (N-3H-imidazo [4,5-B] pyridin-2-YL-methyl)-2-fluoro-4-methyl-3-oxo-4-aza-androst- 1-EN-17. Beta, -carboxamide

Info

Publication number
ZA200804329B
ZA200804329B ZA200804329A ZA200804329A ZA200804329B ZA 200804329 B ZA200804329 B ZA 200804329B ZA 200804329 A ZA200804329 A ZA 200804329A ZA 200804329 A ZA200804329 A ZA 200804329A ZA 200804329 B ZA200804329 B ZA 200804329B
Authority
ZA
South Africa
Prior art keywords
methyl
androst
polymorphs
imidazo
aza
Prior art date
Application number
ZA200804329A
Other languages
English (en)
Inventor
Tan Lushi
Robert S Meissner
Li Wenjie
James J Perkins
Aaron S Cote
Stellabott Joyce
Kiang Yuan-Hon
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37946325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200804329(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA200804329B publication Critical patent/ZA200804329B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200804329A 2005-12-07 2008-05-20 Polymorphs of androgen receptor modulator - (N-3H-imidazo [4,5-B] pyridin-2-YL-methyl)-2-fluoro-4-methyl-3-oxo-4-aza-androst- 1-EN-17. Beta, -carboxamide ZA200804329B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74802805P 2005-12-07 2005-12-07

Publications (1)

Publication Number Publication Date
ZA200804329B true ZA200804329B (en) 2009-04-29

Family

ID=37946325

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804329A ZA200804329B (en) 2005-12-07 2008-05-20 Polymorphs of androgen receptor modulator - (N-3H-imidazo [4,5-B] pyridin-2-YL-methyl)-2-fluoro-4-methyl-3-oxo-4-aza-androst- 1-EN-17. Beta, -carboxamide

Country Status (16)

Country Link
US (1) US7365202B2 (zh)
EP (1) EP1960417B1 (zh)
JP (1) JP2009518404A (zh)
KR (1) KR20080074215A (zh)
CN (1) CN101356185A (zh)
AR (1) AR057217A1 (zh)
AU (1) AU2006322046B2 (zh)
CA (1) CA2631936A1 (zh)
IL (1) IL191692A0 (zh)
NO (1) NO20083046L (zh)
NZ (1) NZ568550A (zh)
PE (1) PE20071091A1 (zh)
RU (1) RU2008127354A (zh)
TW (1) TW200730505A (zh)
WO (1) WO2007067490A1 (zh)
ZA (1) ZA200804329B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20090048283A1 (en) * 2007-08-15 2009-02-19 Lee Claire H Salt of an androgen receptor modulator
CA2886501C (en) * 2007-09-11 2018-03-27 Gtx, Inc. Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN101939009B (zh) 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
WO2016029146A1 (en) * 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
GB202208151D0 (en) * 2022-06-01 2022-07-13 Nzp Uk Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187278A (en) 1990-08-27 1993-02-16 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-aza-5α-androstan-3-one steroids
US7186838B2 (en) * 2002-03-13 2007-03-06 Merck & Co., Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
US7301026B2 (en) * 2005-05-05 2007-11-27 Merck & Co., Inc Process for making fluorinated 4-azasteroid derivatives

Also Published As

Publication number Publication date
AR057217A1 (es) 2007-11-21
KR20080074215A (ko) 2008-08-12
JP2009518404A (ja) 2009-05-07
CA2631936A1 (en) 2007-06-14
US7365202B2 (en) 2008-04-29
PE20071091A1 (es) 2007-11-19
US20070129548A1 (en) 2007-06-07
CN101356185A (zh) 2009-01-28
WO2007067490A1 (en) 2007-06-14
IL191692A0 (en) 2008-12-29
AU2006322046A1 (en) 2007-06-14
NZ568550A (en) 2011-09-30
TW200730505A (en) 2007-08-16
NO20083046L (no) 2008-09-05
EP1960417A1 (en) 2008-08-27
EP1960417B1 (en) 2012-10-17
AU2006322046B2 (en) 2012-01-19
RU2008127354A (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
ZA200804329B (en) Polymorphs of androgen receptor modulator - (N-3H-imidazo [4,5-B] pyridin-2-YL-methyl)-2-fluoro-4-methyl-3-oxo-4-aza-androst- 1-EN-17. Beta, -carboxamide
SI1710241T1 (sl) Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
AP2011005807A0 (en) 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-inflammatory agents.
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
PL2013208T3 (pl) Pirydyno[3,4-B]pirazynowy
IL201973A0 (en) 3,3-spiroindolinone derivatives
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL190094A0 (en) Amino-alkyl-amide derivatives as ccr3 receptor liquids
WO2010062715A3 (en) Polymorphs of dasatinib and process for preparation thereof
EP2142542A4 (en) NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704
HK1101587A1 (en) Method for the preparation of d-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
HK1120520A1 (en) Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes
EP1996192A4 (en) PROCESS FOR PREPARING 3,4-SUBSTITUTED THIAZOLIDIN-2-ONES IN 3,4
GB2476643B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
TWI340746B (en) Naphthyridin derivatives
GB0519831D0 (en) Recliner mechanism
GB2476644B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
HUP0800478A2 (en) Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
ZA201003264B (en) Method for the preparation of 2 chloro1,1,1,2,3,3,3 heptafluopropane
ZA200606861B (en) Improved process for the preparation of 9,11epoxy steroids
PL378551A1 (pl) Sposób wytwarzania 14α-hydroksyandrost-4-en-3,17-dionu